Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Exposure to Antipsychotics and Risk of Stroke: Self Controlled Case Series Study
BMJ 337:616-618,586, Douglas,I.J. &Smeeth,L., 2008
Multiple Ischemic Strokes Associated With Use of Recombinant Activated Factor VII
Arch Neurol 64:879-881, Libman,R.B.,et al, 2007
Adding Aspirin to Clopidogrel After TIA and Ischemic Stroke
Neurol 64:1117-1121, Hankey,G.J. &Eikelboom,J.W., 2005
Risk of Hemorrhagic Stroke With Aspirin Use
Stroke 36:1801-1807, Gorelick,P.B. &Weisman,S.M., 2005
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events
ArchNeurol 57:326-332,306, Hart,R.G.,et al, 2000
Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in patients at High Risk of Vascular Disease?
Stroke 31:1779-1784, Hankey,G.J. et al, 2000
Therapeutic Benefit, Aspirin Revisited in Light of the Introduction of Clopidogrel
Stroke 30:1716-1721, Gorelick,P.B.,et al, 1999
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Ann Int Med 129:394-405, Sharis,P.J.,et al, 1998
Comparison of an Anticoagulation Clinic With Usual Medical Care: Anticoagulation Control, Patient Outcomes, and Health Care Costs
Arch Int Med 158:1641-1647, Chiquette,E.,et al, 1998
Role of Ticlopidine for Prevention of Stroke
Stroke 23:912-916, Albers,G.W., 1992
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Blurred Vision
BMJ 368:m569, Zhou, S.,et al, 2020
Nusinersen in Adult Patients with Spinal Muscular Atrophy
Neurol 95:e413-e416, Moshe-Lilie, O.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
J Stroke Cerebrovasc Dis 29:105216, Jugita, Y.,et al, 2020
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Stroke Incidence and Impact of Continuous-Flow Left Ventricular Assist Devices on Cerebrovascular Physiology
Stroke 50:542-548, Cornwell, W.K.,et al, 2019
Clinical Characteristics and Outcomes of Methamphetamine-Associated Intracerebral Hemorrhage
Neurol 93:e1-e7, Swor, D.E.,et al, 2019
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
A young woman with symmetric weakness and behavioral disturbance
Neurol 90:e1442-e1447, Rosenberg, J.,et al, 2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
NEJM 379:215-225, 291, Johnston, S.C.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Recrudescence of Deficits After Stroke
JAMA Neurol 74:1048-1055, Topcuoglu, M.A.,et al, 2017
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
NEJM 374: DOI:10.1056/NEJMoa1506930, Kernan, W.N.,et al, 2016
Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients with Anticoagulation-Related Intracerebral Hemorrhage
JAMA 313:824-836, Kuramatsu, J.B.,et al, 2015
The Importance of Lesbian, Gay, Bisexual and Transgender Health in Neurology
JAMA Neurol 72:855, Rosendale, N. & Josephson, S.A., 2015
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke
West J Emerg Med 16:175-177, Madden, B. & Chebl, R.B., 2015
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
JAMA Neurol 81:1181-1185, Yaghi, S.,et al, 2014